Burke SK, Mendenhall HV, LaRochelle A, Franano FN. ‘Recombinant Human Pancreatic Elastase (PRT-201) Dilates the Arteriovenous Graft (AVG) Outflow Vein and Increases Graft Blood Flow in a Porcine Femoral AVG Model.’ Poster and Podium presentation at: Vascular Access Society 6th International Congress; 2009 April 20-22; Rome, Italy. Summary: AVG surgery is often initially successful but ultimately […]
Category Archives: Presentations
Saturable Drug Binding Explains the Dose and Tissue Dependence of Stent Delivery.’ FDA/NHLBI/NSF Workshop on Computer Methods for Cardiovascular Devices: Saturable Drug Binding Explains the Dose and Tissue Dependence of Stent Delivery
Tzafriri AR, Edelman ER. ‘Saturable Drug Binding Explains the Dose and Tissue Dependence of Stent Delivery.’ FDA/NHLBI/NSF Workshop on Computer Methods for Cardiovascular Devices, Bethesda, MD, 2009.
American Society of Nephrology: Local Application of Recombinant Human Type I Pancreatic Elastase (PRT-201) to an Arteriovenous Fistula (AVF) Increases AVF Blood Flow in a Rabbit Model
Burke SK, FNF, LaRochelle Alan, Mendenhall HV. ‘Local Application of Recombinant Human Type I Pancreatic Elastase (PRT-201) to an Arteriovenous Fistula (AVF) Increases AVF Blood Flow in a Rabbit Model.’ American Society of Nephrology, Philadelphia, PA, 2008.
TCT 2006 : Dissociating DES safety & efficacy: Endothelial regrowth & drug effect after abluminal or circumferential paclitaxel delivery from bioerodable polymer in porcine coronaries
Spognardi AM. ‘Dissociating DES safety & efficacy: Endothelial regrowth & drug effect after abluminal or circumferential paclitaxel delivery from bioerodable polymer in porcine coronaries.’ Transcatheter Cardiovascular Therapeutics, Washington, DC, 2006.
TCT 2006 : Self-expanding Coronary Stents Entirely Incorporated within an 0.014” Wire: Late Lumen Gain 90 days after Porcine Coronary Artery Implantation
Spognardi AM. ‘Self-expanding Coronary Stents Entirely Incorporated within an 0.014” Wire: Late Lumen Gain 90 days after Porcine Coronary Artery Implantation.’ Transcatheter Cardiovascular Therapeutics, Washington, DC, 2006.
TCT 2005: Total Paclitaxel Dose Optimization With Minimized Abluminal Bioerodable Polymer Stent Coatings Provides Safe Delivery of Paclitaxel in Porcine Coronary Arteries
Spognardi AM. ‘Total Paclitaxel Dose Optimization With Minimized Abluminal Bioerodable Polymer Stent Coatings Provides Safe Delivery of Paclitaxel in Porcine Coronary Arteries.’ Transcatheter Cardiovascular Therapeutics, Washington, DC, 2005.
TCT 2004: Abluminal bioerodable polymer stent coating, applicable at point-of-care, provides safe delivery of paclitaxel in porcine coronary arteries
Spognardi AM. ‘Abluminal bioerodable polymer stent coating, applicable at point-of-care, provides safe delivery of paclitaxel in porcine coronary arteries.’ Transcatheter Cardiovascular Therapeutics, Washington, DC, 2004.